Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Mark

Showing results (481-490 of 535) with videos related to

Pageof 54
Sort By:
Blood Advances|April 21, 2020
Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progressionZachary J Walker, Michael J VanWyngarden, Brett M Stevens, et al.
Cancer|November 6, 2018
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myelomaAjai Chari, Sagar Lonial, Tomer M Mark, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|March 16, 2001
Use of hearts transplanted from donors with atraumatic intracranial bleedsD Marelli, F Tsai, H Laks, et al.
Heliyon|June 25, 2020
Using critical care physicians to deliver anesthesia and boost surgical caseload in austere environments: the Critical Care General Anesthesia Syllabus (CC GAS)Quincy K Tran, Natalie M Mark, Lia I Losonczy, et al.
Blood|October 22, 2008
IL-17 contributes to CD4-mediated graft-versus-host diseaseLucy W Kappel, Gabrielle L Goldberg, Christopher G King, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2020
Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based TherapyZachary J Walker, Beau M Idler, Lorraine N Davis, et al.
Blood Advances|August 30, 2023
CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapiesOlivia Perez de Acha, Lauren Reiman, David S Jayabalan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 13, 2017
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple MyelomaTomer M Mark, Danielle Guarneri, Peter Forsberg, et al.
Nature Communications|November 6, 2019
A novel mouse model demonstrates that oncogenic melanocyte stem cells engender melanoma resembling human diseaseQi Sun, Wendy Lee, Yasuaki Mohri, et al.
American Journal of Hematology|August 23, 2021
Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myelomaPeter A Forsberg, Adriana C Rossi, Angelique Boyer, et al.
Pageof 54

Showing results (481-490 of 535) with videos related to

Sort By:
Pageof 54
Blood Advances|April 21, 2020
Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progressionZachary J Walker, Michael J VanWyngarden, Brett M Stevens, et al.
Cancer|November 6, 2018
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myelomaAjai Chari, Sagar Lonial, Tomer M Mark, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|March 16, 2001
Use of hearts transplanted from donors with atraumatic intracranial bleedsD Marelli, F Tsai, H Laks, et al.
Heliyon|June 25, 2020
Using critical care physicians to deliver anesthesia and boost surgical caseload in austere environments: the Critical Care General Anesthesia Syllabus (CC GAS)Quincy K Tran, Natalie M Mark, Lia I Losonczy, et al.
Blood|October 22, 2008
IL-17 contributes to CD4-mediated graft-versus-host diseaseLucy W Kappel, Gabrielle L Goldberg, Christopher G King, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2020
Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based TherapyZachary J Walker, Beau M Idler, Lorraine N Davis, et al.
Blood Advances|August 30, 2023
CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapiesOlivia Perez de Acha, Lauren Reiman, David S Jayabalan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 13, 2017
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple MyelomaTomer M Mark, Danielle Guarneri, Peter Forsberg, et al.
Nature Communications|November 6, 2019
A novel mouse model demonstrates that oncogenic melanocyte stem cells engender melanoma resembling human diseaseQi Sun, Wendy Lee, Yasuaki Mohri, et al.
American Journal of Hematology|August 23, 2021
Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myelomaPeter A Forsberg, Adriana C Rossi, Angelique Boyer, et al.
Pageof 54